SG11201510816SA - Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist - Google Patents

Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist

Info

Publication number
SG11201510816SA
SG11201510816SA SG11201510816SA SG11201510816SA SG11201510816SA SG 11201510816S A SG11201510816S A SG 11201510816SA SG 11201510816S A SG11201510816S A SG 11201510816SA SG 11201510816S A SG11201510816S A SG 11201510816SA SG 11201510816S A SG11201510816S A SG 11201510816SA
Authority
SG
Singapore
Prior art keywords
mrna
gene expression
cancer therapy
based gene
patient cancer
Prior art date
Application number
SG11201510816SA
Other languages
English (en)
Inventor
Gong Chen
Markus Dangl
David Geho
Gwen Nichols
Hua Zhong
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201510816SA publication Critical patent/SG11201510816SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Epidemiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201510816SA 2013-07-03 2014-07-02 Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist SG11201510816SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361842567P 2013-07-03 2013-07-03
US201361912781P 2013-12-06 2013-12-06
PCT/EP2014/064039 WO2015000945A1 (en) 2013-07-03 2014-07-02 Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist

Publications (1)

Publication Number Publication Date
SG11201510816SA true SG11201510816SA (en) 2016-01-28

Family

ID=51162759

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201510816SA SG11201510816SA (en) 2013-07-03 2014-07-02 Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist

Country Status (13)

Country Link
EP (1) EP3017061B1 (ja)
JP (2) JP6461126B2 (ja)
KR (1) KR101879926B1 (ja)
CN (1) CN105378112B (ja)
AU (1) AU2014286237B2 (ja)
BR (1) BR112015031542A2 (ja)
CA (1) CA2912547A1 (ja)
HK (1) HK1215453A1 (ja)
IL (1) IL242692B (ja)
MX (1) MX363584B (ja)
RU (1) RU2016101514A (ja)
SG (1) SG11201510816SA (ja)
WO (1) WO2015000945A1 (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101623985B1 (ko) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
JP6342808B2 (ja) 2011-10-18 2018-06-13 エイルロン セラピューティクス，インコーポレイテッド ペプチドミメティック大環状化合物
AU2013221433B2 (en) 2012-02-15 2018-01-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
WO2015108175A1 (en) * 2014-01-14 2015-07-23 Daiichi Sankyo Company, Limited Gene signatures associated with sensitivity to mdm2 inhibitors
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
CN107106642B (zh) 2014-09-24 2021-02-26 艾瑞朗医疗公司 拟肽大环化合物及其制剂
WO2016056673A1 (en) * 2014-10-09 2016-04-14 Daiichi Sankyo Company, Limited Algorithms for gene signature-based predictor of sensitivity to mdm2 inhibitors
CN107427501B (zh) 2015-02-20 2023-12-01 第一三共株式会社 通过联合使用治疗癌症的方法
CA2979847A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
US10471154B2 (en) * 2016-08-08 2019-11-12 Fei Xiao Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
WO2020018611A1 (en) * 2018-07-18 2020-01-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of ewing sarcoma using tp53 dependency biomarkers and modulators
KR20180093849A (ko) 2018-08-09 2018-08-22 가톨릭대학교 산학협력단 줄기세포 사멸 예측 마커 및 이의 용도
WO2020124043A1 (en) * 2018-12-13 2020-06-18 Gordon Erlinda M Methods of exploiting oncogenic drivers along the human cyclin g1 pathway for cancer gene therapy
KR20190060964A (ko) 2019-05-24 2019-06-04 가톨릭대학교 산학협력단 줄기세포 사멸 예측 마커 및 이의 용도
GB201919219D0 (en) * 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
CA3181715A1 (en) * 2020-08-27 2022-03-03 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using mdm2 antagonists
RU2766739C1 (ru) * 2021-04-12 2022-03-15 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Способ прогноза эффективности терапии меланомы

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2527285A1 (en) * 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
ES2538714T3 (es) 2005-12-01 2015-06-23 F. Hoffmann-La Roche Ag Derivados de 2,4,5-trifenil-imidazolina como inhibidores de la interacción entre las proteínas p53 y MDM2 para el uso en calidad de agentes anticancerosos
DK2568053T3 (da) * 2008-05-12 2014-07-21 Genomic Health Inc Tests til forudsigelse af cancerpatienters respons på forskellige kemoterapeutiske behandlingsmuligheder
RS52660B (en) 2008-09-18 2013-06-28 F. Hoffmann-La Roche Ag SUBSTITUTED PYROLIDINE-2-CARBOXAMIDES
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
US20120046186A1 (en) * 2010-08-20 2012-02-23 Pelham Robert J Gene Expression Markers for Prediction of Response to Platinum-Based Chemotherapy Drugs
US8993614B2 (en) * 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides

Also Published As

Publication number Publication date
MX2015018051A (es) 2016-03-16
CN105378112B (zh) 2020-10-13
RU2016101514A3 (ja) 2018-05-28
EP3017061B1 (en) 2019-01-02
WO2015000945A1 (en) 2015-01-08
AU2014286237A1 (en) 2016-01-28
AU2014286237B2 (en) 2020-08-20
CA2912547A1 (en) 2015-01-08
BR112015031542A2 (pt) 2017-07-25
JP2019059737A (ja) 2019-04-18
KR101879926B1 (ko) 2018-08-16
KR20160013214A (ko) 2016-02-03
HK1215453A1 (zh) 2016-08-26
EP3017061A1 (en) 2016-05-11
IL242692B (en) 2019-12-31
MX363584B (es) 2019-03-27
RU2016101514A (ru) 2017-08-08
CN105378112A (zh) 2016-03-02
JP6461126B2 (ja) 2019-01-30
JP2016529880A (ja) 2016-09-29

Similar Documents

Publication Publication Date Title
IL242692B (en) Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist
IL245731A0 (en) Combined treatment for cancer
GB201322725D0 (en) Cancer therapy
PT3033086T (pt) Terapia de combinação para o tratamento de cancro
EP2968343A4 (en) POLY THERAPY FOR TREATING CANCER
HK1201755A1 (en) Treatment of cancer with tor kinase inhibitors tor
HK1205691A1 (en) Dual ox40 agonist/il-2 cancer therapy methods ox40 /il-2
HK1202247A1 (en) Treatment of cancer with tor kinase inhibitors tor
HK1201750A1 (en) Treatment of cancer with tor kinase inhibitors tor
HK1201753A1 (en) Treatment of cancer with tor kinase inhibitors tor
HK1220900A1 (zh) 癌症的治療
HK1214611A1 (zh) 作為癌症治療和診斷靶標的
EP2994148B8 (en) Cancer therapy
LT3077544T (lt) Racionalia logika pagrįstas tikslinės vėžio terapijos modelis
HK1207013A1 (en) Catheter for photodynamic therapy
EP3088001A4 (en) Therapeutic drug for malignant tumors
EP3044593A4 (en) Cancer therapy
EP2961412A4 (en) CANCER THERAPY
HK1209725A1 (en) Bendamustine derivatives and related compounds, and medical use thereof cancer therapy
EP2934500A4 (en) COMBINATION THERAPY AGAINST CANCER
HK1218939A1 (zh) 用於非小細胞肺癌療法的藥物選擇
HK1213475A1 (zh) 用於癌症治療的 、卡培他濱和奧沙利鉑的組合
EP3058960A4 (en) Diagnostic agent for therapeutic effect on cancer
GB201518731D0 (en) Tumour Therapy
IL239231A0 (en) Combined cancer treatment